Rocket Lab Shares Gain Momentum Amid Sector Strength and Operational Milestones

Rocket Lab USA’s stock experienced a notable uplift this week, propelled by a combination of broader geopolitical trends and company-specific progress. The dual catalysts have investors evaluating the sustainability of the move ahead of the firm’s upcoming earnings release.

Operational Execution Provides Foundation

On the operational front, Rocket Lab recently completed the 80th mission of its Electron rocket, successfully deploying satellites for Open Cosmos. This achievement reinforces confidence in the company’s increasing launch cadence and its competitive stance within the small satellite launch services market.

Concurrently, the company is advancing its defense segment. A mission dubbed “Cassowary Vex” is scheduled for late February. This would mark the fourth hypersonic test conducted in under six months using the HASTE (Hypersonic Accelerator Suborbital Test Electron) system for the Defense Innovation Unit. The initiative aims to reduce costs and increase testing frequency, positioning Rocket Lab as a provider of relatively affordable hypersonic testing capabilities for U.S. defense applications.

Broad Sector Rally Lifts Shares

The immediate trigger for the share price advance was a widespread rally across aerospace and defense equities. This sector-wide strength was reportedly driven by escalating geopolitical tensions between the United States and Iran. According to Benzinga, relevant industry ETFs climbed approximately 2%. Rocket Lab emerged as a beneficiary, with its shares advancing more than 7% on February 18. The stock reached an intraday high of $75.72 before closing at $75.13, as reported by GuruFocus.

This recovery follows a period of weakness. In the roughly four weeks preceding this jump, the equity had shed about 16% of its value. General market concerns and speculation around a potential SpaceX initial public offering, which was seen as potentially drawing capital away from the competitive landscape, were cited as contributing factors to the earlier decline.

Should investors sell immediately? Or is it worth buying Rocket Lab USA?

Upcoming Earnings and the Crucial Neutron Timeline

Market attention now turns to Rocket Lab’s fourth-quarter and full-year 2025 financial results, scheduled for release on February 26. Analyst consensus, per Benzinga, anticipates revenue of approximately $178 million, up from $132 million in the prior year, alongside an adjusted loss of nine cents per share. The report is also expected to provide details on backlog conversion, margin progression, and, most critically, the development timeline for the larger Neutron rocket program.

This program recently encountered a setback. Reports indicate a crack was discovered in a Stage-1 tank during a pressure test. This development clouds expectations for the larger launch vehicle’s maiden flight and could potentially delay the planned launch schedule—a risk factor looming just ahead of the earnings announcement.

Analysts have issued several recent adjustments. Bank of America raised its price target to $120 with a Buy rating. Goldman Sachs increased its target to $69, maintaining a Neutral stance. Morgan Stanley upgraded the stock to Overweight, citing a target near $105, while TD Cowen maintained its Buy recommendation.

The February 26 earnings report will likely determine whether the combination of defense sector momentum and Electron execution is translating convincingly to the financial metrics. Furthermore, it will reveal if Rocket Lab can provide concrete, reliable updates on the Neutron schedule despite the recent testing incident.